157 related articles for article (PubMed ID: 36428744)
21. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.
Yang F; Wang Y; Tang L; Mansfield AS; Adjei AA; Leventakos K; Duma N; Wei J; Wang L; Liu B; Molina JR
Front Oncol; 2022; 12():955440. PubMed ID: 36052255
[TBL] [Abstract][Full Text] [Related]
22. The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer.
Wei J; Feng J; Weng Y; Xu Z; Jin Y; Wang P; Cui X; Ruan P; Luo R; Li N; Peng M
Front Oncol; 2021; 11():706910. PubMed ID: 34660274
[TBL] [Abstract][Full Text] [Related]
23. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y
Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.
Nie W; Qian J; Xu MD; Gu K; Qian FF; Lu J; Zhang XY; Wang HM; Yan B; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
J Natl Compr Canc Netw; 2020 May; 18(5):582-589. PubMed ID: 32380463
[TBL] [Abstract][Full Text] [Related]
25. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
26. Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Ma Y; Li Q; Du Y; Cai J; Chen W; Zhao G; Liu X; Li H; Ma L; Huang Y; Zhou Y
Front Oncol; 2021; 11():640761. PubMed ID: 34055609
[TBL] [Abstract][Full Text] [Related]
27. Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring
Nie W; Gan L; Wang X; Gu K; Qian FF; Hu MJ; Zhang D; Chen SQ; Lu J; Cao SH; Li JW; Wang Y; Zhang B; Wang SY; Li CH; Yang P; Xu MD; Zhang XY; Zhong H; Han BH
Oncoimmunology; 2021 Jan; 10(1):1865670. PubMed ID: 33537171
[TBL] [Abstract][Full Text] [Related]
28. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.
Liu M; Xia S; Zhang X; Zhang B; Yan L; Yang M; Ren Y; Guo H; Zhao J
Lung Cancer; 2022 Aug; 170():148-155. PubMed ID: 35792434
[TBL] [Abstract][Full Text] [Related]
30. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Dong Y; Zhao L; Duan J; Bai H; Chen D; Li S; Yu Y; Xiao M; Zhang Q; Duan Q; Sun T; Qi C; Wang J; Wang Z
Cell Prolif; 2022 Sep; 55(9):e13283. PubMed ID: 35811392
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
[TBL] [Abstract][Full Text] [Related]
32. ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
Chen Y; Li X; Liu G; Chen S; Xu M; Song L; Wang Y
Front Oncol; 2020; 10():1706. PubMed ID: 33014846
[TBL] [Abstract][Full Text] [Related]
33. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
34. Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC.
Liu Z; Xie Z; Zhao S; Ye D; Cai X; Cheng B; Li C; Xiong S; Li J; Liang H; Chen Z; Liang P; Liu J; He J; Liang W
Transl Lung Cancer Res; 2019 Dec; 8(6):1045-1050. PubMed ID: 32010581
[TBL] [Abstract][Full Text] [Related]
35. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
[TBL] [Abstract][Full Text] [Related]
36. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
37. Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer.
Shi J; Wang Z; Zhang J; Xu Y; Xiao X; Quan X; Bai Y; Yang X; Ming Z; Guo X; Feng H; Yang X; Zhuang X; Han F; Wang K; Shi Y; Lei Y; Bai J; Yang S
Clin Cancer Res; 2021 Nov; 27(22):6184-6196. PubMed ID: 34446541
[TBL] [Abstract][Full Text] [Related]
38. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Zhu C; Zhuang W; Chen L; Yang W; Ou WB
Transl Lung Cancer Res; 2020 Feb; 9(1):111-138. PubMed ID: 32206559
[TBL] [Abstract][Full Text] [Related]
39. Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients.
Lu J; Wu J; Lou Y; Shi Q; Xu J; Zhang L; Nie W; Qian J; Wang Y; Zhang Y; Jiao J; Zhang X; Zhang W; Wang H; Chu T; Zhong H; Han B
Biomark Res; 2022 Jul; 10(1):55. PubMed ID: 35906676
[TBL] [Abstract][Full Text] [Related]
40. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]